JP2007532665A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007532665A5 JP2007532665A5 JP2007508496A JP2007508496A JP2007532665A5 JP 2007532665 A5 JP2007532665 A5 JP 2007532665A5 JP 2007508496 A JP2007508496 A JP 2007508496A JP 2007508496 A JP2007508496 A JP 2007508496A JP 2007532665 A5 JP2007532665 A5 JP 2007532665A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- formula
- hiv integrase
- compound
- integrase inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 262
- 229940099797 HIV integrase inhibitor Drugs 0.000 claims 165
- 239000003084 hiv integrase inhibitor Substances 0.000 claims 165
- 125000000623 heterocyclic group Chemical group 0.000 claims 34
- 125000003107 substituted aryl group Chemical group 0.000 claims 32
- 125000003118 aryl group Chemical group 0.000 claims 31
- 125000000217 alkyl group Chemical group 0.000 claims 28
- 239000000651 prodrug Substances 0.000 claims 28
- 229940002612 prodrug Drugs 0.000 claims 28
- 125000001072 heteroaryl group Chemical group 0.000 claims 26
- 229910052799 carbon Inorganic materials 0.000 claims 23
- 125000000547 substituted alkyl group Chemical group 0.000 claims 22
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 claims 19
- -1 polyethyleneoxy Polymers 0.000 claims 19
- 125000005017 substituted alkenyl group Chemical group 0.000 claims 19
- 125000003342 alkenyl group Chemical group 0.000 claims 18
- 125000000304 alkynyl group Chemical group 0.000 claims 18
- 229910052739 hydrogen Inorganic materials 0.000 claims 17
- 125000004426 substituted alkynyl group Chemical group 0.000 claims 17
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical group OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 claims 15
- 239000000203 mixture Substances 0.000 claims 15
- 125000006239 protecting group Chemical group 0.000 claims 15
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 claims 13
- 229910019142 PO4 Inorganic materials 0.000 claims 12
- 125000003282 alkyl amino group Chemical group 0.000 claims 12
- 125000004432 carbon atom Chemical group C* 0.000 claims 12
- 150000003951 lactams Chemical class 0.000 claims 12
- 229910052760 oxygen Inorganic materials 0.000 claims 12
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 12
- 239000010452 phosphate Substances 0.000 claims 12
- 229940124530 sulfonamide Drugs 0.000 claims 12
- 150000003456 sulfonamides Chemical class 0.000 claims 12
- 229910052717 sulfur Inorganic materials 0.000 claims 12
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 10
- IIACRCGMVDHOTQ-UHFFFAOYSA-M sulfamate Chemical compound NS([O-])(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-M 0.000 claims 10
- 150000001408 amides Chemical class 0.000 claims 9
- 230000000694 effects Effects 0.000 claims 9
- 150000002148 esters Chemical class 0.000 claims 9
- 150000002596 lactones Chemical class 0.000 claims 9
- 229910052757 nitrogen Inorganic materials 0.000 claims 9
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 8
- 125000005360 alkyl sulfoxide group Chemical group 0.000 claims 8
- 125000002947 alkylene group Chemical group 0.000 claims 8
- 125000004419 alkynylene group Chemical group 0.000 claims 8
- 125000005361 aryl sulfoxide group Chemical group 0.000 claims 8
- 125000005110 aryl thio group Chemical group 0.000 claims 8
- 150000001721 carbon Chemical group 0.000 claims 8
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 8
- 150000002825 nitriles Chemical class 0.000 claims 7
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims 6
- 125000004450 alkenylene group Chemical group 0.000 claims 6
- 125000004663 dialkyl amino group Chemical group 0.000 claims 6
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims 6
- 125000005842 heteroatom Chemical group 0.000 claims 6
- 239000003112 inhibitor Substances 0.000 claims 6
- 238000000034 method Methods 0.000 claims 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 6
- 125000001424 substituent group Chemical group 0.000 claims 6
- 125000005208 trialkylammonium group Chemical group 0.000 claims 6
- 125000003545 alkoxy group Chemical group 0.000 claims 5
- 150000001540 azides Chemical class 0.000 claims 5
- 238000006467 substitution reaction Methods 0.000 claims 5
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 claims 4
- 150000001350 alkyl halides Chemical class 0.000 claims 4
- 150000008052 alkyl sulfonates Chemical class 0.000 claims 4
- 125000002837 carbocyclic group Chemical group 0.000 claims 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 4
- 150000007942 carboxylates Chemical class 0.000 claims 4
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 4
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 4
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 4
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 4
- 230000003834 intracellular effect Effects 0.000 claims 4
- 210000000265 leukocyte Anatomy 0.000 claims 4
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 150000003457 sulfones Chemical class 0.000 claims 4
- 150000003462 sulfoxides Chemical class 0.000 claims 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 3
- 108010002459 HIV Integrase Proteins 0.000 claims 3
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 claims 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 3
- 125000004122 cyclic group Chemical group 0.000 claims 3
- 239000003937 drug carrier Substances 0.000 claims 3
- OUUQCZGPVNCOIJ-UHFFFAOYSA-N hydroperoxyl Chemical group O[O] OUUQCZGPVNCOIJ-UHFFFAOYSA-N 0.000 claims 3
- 239000002207 metabolite Substances 0.000 claims 3
- 208000030507 AIDS Diseases 0.000 claims 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical group C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 claims 2
- 150000001356 alkyl thiols Chemical class 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 238000006243 chemical reaction Methods 0.000 claims 2
- 125000005843 halogen group Chemical group 0.000 claims 2
- 125000005241 heteroarylamino group Chemical group 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- GZGZMAJKCUAIRS-UHFFFAOYSA-N piperazin-1-yl sulfamate Chemical compound NS(=O)(=O)ON1CCNCC1 GZGZMAJKCUAIRS-UHFFFAOYSA-N 0.000 claims 2
- 125000004193 piperazinyl group Chemical group 0.000 claims 2
- 125000003386 piperidinyl group Chemical group 0.000 claims 2
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 claims 2
- 125000004076 pyridyl group Chemical group 0.000 claims 2
- IIACRCGMVDHOTQ-UHFFFAOYSA-N sulfamic acid Chemical class NS(O)(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-N 0.000 claims 2
- 150000003467 sulfuric acid derivatives Chemical class 0.000 claims 2
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 2
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims 2
- 125000001544 thienyl group Chemical group 0.000 claims 2
- 150000003573 thiols Chemical class 0.000 claims 2
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims 1
- 125000006619 (C1-C6) dialkylamino group Chemical group 0.000 claims 1
- HFHDGHOGHWXXDT-ZSOIEALJSA-N (z)-1-[5-[(4-fluorophenyl)methyl]furan-2-yl]-3-hydroxy-3-(1h-1,2,4-triazol-5-yl)prop-2-en-1-one Chemical compound N=1C=NNC=1C(/O)=C/C(=O)C(O1)=CC=C1CC1=CC=C(F)C=C1 HFHDGHOGHWXXDT-ZSOIEALJSA-N 0.000 claims 1
- QGCIARGIIYMTGU-PTNGSMBKSA-N (z)-4-(3-benzylphenyl)-4-hydroxy-2-oxobut-3-enoic acid Chemical compound OC(=O)C(=O)\C=C(/O)C1=CC=CC(CC=2C=CC=CC=2)=C1 QGCIARGIIYMTGU-PTNGSMBKSA-N 0.000 claims 1
- RLOQBKJCOAXOLR-UHFFFAOYSA-N 1h-pyrrole-2-carboxamide Chemical compound NC(=O)C1=CC=CN1 RLOQBKJCOAXOLR-UHFFFAOYSA-N 0.000 claims 1
- 125000004176 4-fluorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1F)C([H])([H])* 0.000 claims 1
- NSPMIYGKQJPBQR-UHFFFAOYSA-N 4H-1,2,4-triazole Chemical compound C=1N=CNN=1 NSPMIYGKQJPBQR-UHFFFAOYSA-N 0.000 claims 1
- 208000031886 HIV Infections Diseases 0.000 claims 1
- 208000037357 HIV infectious disease Diseases 0.000 claims 1
- 229940122440 HIV protease inhibitor Drugs 0.000 claims 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims 1
- 241001465754 Metazoa Species 0.000 claims 1
- 229940122313 Nucleoside reverse transcriptase inhibitor Drugs 0.000 claims 1
- 101710101148 Probable 6-oxopurine nucleoside phosphorylase Proteins 0.000 claims 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims 1
- 102000030764 Purine-nucleoside phosphorylase Human genes 0.000 claims 1
- 230000002378 acidificating effect Effects 0.000 claims 1
- 125000006323 alkenyl amino group Chemical group 0.000 claims 1
- 125000004849 alkoxymethyl group Chemical group 0.000 claims 1
- 125000003806 alkyl carbonyl amino group Chemical group 0.000 claims 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims 1
- 125000006319 alkynyl amino group Chemical group 0.000 claims 1
- 125000002431 aminoalkoxy group Chemical group 0.000 claims 1
- 230000001093 anti-cancer Effects 0.000 claims 1
- 230000002924 anti-infective effect Effects 0.000 claims 1
- 230000003110 anti-inflammatory effect Effects 0.000 claims 1
- 230000000340 anti-metabolite Effects 0.000 claims 1
- 229960005475 antiinfective agent Drugs 0.000 claims 1
- 229940100197 antimetabolite Drugs 0.000 claims 1
- 239000002256 antimetabolite Substances 0.000 claims 1
- 125000001769 aryl amino group Chemical group 0.000 claims 1
- 125000004658 aryl carbonyl amino group Chemical group 0.000 claims 1
- 125000000732 arylene group Chemical group 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims 1
- 125000004541 benzoxazolyl group Chemical class O1C(=NC2=C1C=CC=C2)* 0.000 claims 1
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims 1
- 150000001732 carboxylic acid derivatives Chemical group 0.000 claims 1
- YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical group OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical group C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 125000004185 ester group Chemical group 0.000 claims 1
- 125000003709 fluoroalkyl group Chemical group 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 239000004030 hiv protease inhibitor Substances 0.000 claims 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 230000002519 immonomodulatory effect Effects 0.000 claims 1
- 239000002955 immunomodulating agent Substances 0.000 claims 1
- 229940121354 immunomodulator Drugs 0.000 claims 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 claims 1
- 125000001041 indolyl group Chemical group 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 125000005647 linker group Chemical group 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000013160 medical therapy Methods 0.000 claims 1
- 208000030159 metabolic disease Diseases 0.000 claims 1
- 239000000178 monomer Substances 0.000 claims 1
- 125000001624 naphthyl group Chemical group 0.000 claims 1
- 229940042402 non-nucleoside reverse transcriptase inhibitor Drugs 0.000 claims 1
- 239000002726 nonnucleoside reverse transcriptase inhibitor Substances 0.000 claims 1
- 239000002777 nucleoside Substances 0.000 claims 1
- 150000003833 nucleoside derivatives Chemical class 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 239000001301 oxygen Substances 0.000 claims 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 239000002243 precursor Substances 0.000 claims 1
- 125000003226 pyrazolyl group Chemical group 0.000 claims 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 1
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 claims 1
- 125000003003 spiro group Chemical group 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 230000002194 synthesizing effect Effects 0.000 claims 1
- 230000008685 targeting Effects 0.000 claims 1
- 150000003536 tetrazoles Chemical class 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 125000004665 trialkylsilyl group Chemical group 0.000 claims 1
- 150000003852 triazoles Chemical class 0.000 claims 1
- 125000004950 trifluoroalkyl group Chemical group 0.000 claims 1
- 0 C[C@](CCC1(C(C)(C)O)OC1)[C@@]1[C@]([C@]([C@@](C2=C3CCC(C(C)(C)[C@]4*)[C@]2(C)C[C@]4O*)O)O)(C(C)=O)C3=CC1 Chemical compound C[C@](CCC1(C(C)(C)O)OC1)[C@@]1[C@]([C@]([C@@](C2=C3CCC(C(C)(C)[C@]4*)[C@]2(C)C[C@]4O*)O)O)(C(C)=O)C3=CC1 0.000 description 26
- CDRSBPYJKRZQAY-UHFFFAOYSA-N COC(N1CCOCC1)=O Chemical compound COC(N1CCOCC1)=O CDRSBPYJKRZQAY-UHFFFAOYSA-N 0.000 description 1
- BVCPOBBMOIJWQM-UHFFFAOYSA-N COS(N1CCOCC1)(=O)=O Chemical compound COS(N1CCOCC1)(=O)=O BVCPOBBMOIJWQM-UHFFFAOYSA-N 0.000 description 1
- WXSIWFBRRFAVJQ-UHFFFAOYSA-N O=C(CC1CC1)N1CCOCC1 Chemical compound O=C(CC1CC1)N1CCOCC1 WXSIWFBRRFAVJQ-UHFFFAOYSA-N 0.000 description 1
- PVBOVFLECGDSBT-UHFFFAOYSA-N O=C(c(cccc1)c1S)NNC(c1ccccc1SSc(cc(cc1)I)c1C(NNC(c(cccc1)c1S)=O)=O)=O Chemical compound O=C(c(cccc1)c1S)NNC(c1ccccc1SSc(cc(cc1)I)c1C(NNC(c(cccc1)c1S)=O)=O)=O PVBOVFLECGDSBT-UHFFFAOYSA-N 0.000 description 1
- UXDSBDGMFUNUCO-UHFFFAOYSA-N O=C(c(cccc1)c1S)NNC(c1ccccc1SSc(cccc1)c1C(NNC(c(c([AlH2])ccc1)c1S)=O)=O)=O Chemical compound O=C(c(cccc1)c1S)NNC(c1ccccc1SSc(cccc1)c1C(NNC(c(c([AlH2])ccc1)c1S)=O)=O)=O UXDSBDGMFUNUCO-UHFFFAOYSA-N 0.000 description 1
- ATIQTVUVGCQYEV-UHFFFAOYSA-N O=C(c(cccc1)c1SSc(cccc1)c1C(NNC(c(ccc(I)c1)c1SSc1c2cccc1)=O)=O)NNC2=O Chemical compound O=C(c(cccc1)c1SSc(cccc1)c1C(NNC(c(ccc(I)c1)c1SSc1c2cccc1)=O)=O)NNC2=O ATIQTVUVGCQYEV-UHFFFAOYSA-N 0.000 description 1
- QHZMUUXGGURBEN-UHFFFAOYSA-M OC(C1OC(c(cc2O)cc(O[AlH2])c2O)=O)C(O)OC1OC1=C(c(cc2)cc(O)c2O)Oc2cc(O)cc(O)c2C1=O Chemical compound OC(C1OC(c(cc2O)cc(O[AlH2])c2O)=O)C(O)OC1OC1=C(c(cc2)cc(O)c2O)Oc2cc(O)cc(O)c2C1=O QHZMUUXGGURBEN-UHFFFAOYSA-M 0.000 description 1
- BHSGUMGKESMLOG-UHFFFAOYSA-N OC(c(cc1O)cc(O)c1O)OC(C1O)C(OC(C(c2c(cc3O)O)=O)=C(C(CC4O)=CC=C4O)Oc2c3[AlH2])OC1O Chemical compound OC(c(cc1O)cc(O)c1O)OC(C1O)C(OC(C(c2c(cc3O)O)=O)=C(C(CC4O)=CC=C4O)Oc2c3[AlH2])OC1O BHSGUMGKESMLOG-UHFFFAOYSA-N 0.000 description 1
- ARMGDESJBVCPBB-UHFFFAOYSA-N OC(c(cc1O)cc(O)c1O)OC(C1O)C(OC2=C(c(cc3)cc(O)c3O)Oc3cc(O)cc(O)c3C2=O)OC1O Chemical compound OC(c(cc1O)cc(O)c1O)OC(C1O)C(OC2=C(c(cc3)cc(O)c3O)Oc3cc(O)cc(O)c3C2=O)OC1O ARMGDESJBVCPBB-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US56267804P | 2004-04-14 | 2004-04-14 | |
| PCT/US2005/012520 WO2005117904A2 (en) | 2004-04-14 | 2005-04-11 | Phosphonate analogs of hiv integrase inhibitor compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007532665A JP2007532665A (ja) | 2007-11-15 |
| JP2007532665A5 true JP2007532665A5 (enExample) | 2008-06-19 |
Family
ID=35276373
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007508496A Pending JP2007532665A (ja) | 2004-04-14 | 2005-04-11 | Ｈｉｖインテグラーゼ阻害剤化合物のホスホネート類似物 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20080076738A1 (enExample) |
| EP (1) | EP1742642B1 (enExample) |
| JP (1) | JP2007532665A (enExample) |
| AT (1) | ATE411030T1 (enExample) |
| AU (1) | AU2005249363A1 (enExample) |
| CA (1) | CA2562713A1 (enExample) |
| DE (1) | DE602005010413D1 (enExample) |
| DK (1) | DK1742642T3 (enExample) |
| ES (1) | ES2315922T3 (enExample) |
| PL (1) | PL1742642T3 (enExample) |
| PT (1) | PT1742642E (enExample) |
| SI (1) | SI1742642T1 (enExample) |
| WO (1) | WO2005117904A2 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003301439A1 (en) * | 2002-10-16 | 2004-05-04 | Gilead Sciences, Inc. | Pre-organized tricyclic integrase inhibitor compounds |
| EP1888581A2 (en) * | 2005-05-16 | 2008-02-20 | Gilead Sciences, Inc. | Hiv-integrase inhibitor compounds |
| EP1885722B1 (en) | 2005-05-19 | 2011-11-16 | Merck Canada Inc. | Quinoline derivatives as ep4 antagonists |
| WO2007014352A2 (en) * | 2005-07-27 | 2007-02-01 | Gilead Sciences, Inc. | Antiviral phosphonate conjugates for inhibition of hiv |
| EP1987046A1 (en) * | 2006-02-20 | 2008-11-05 | Alembic Limited | An improved process for the preparation of biphosphonic derivatives |
| CA2651579A1 (en) | 2006-05-16 | 2007-11-29 | Gilead Sciences, Inc. | Integrase inhibitors |
| WO2009026206A1 (en) * | 2007-08-21 | 2009-02-26 | University Of Toledo | Method for synthesizing xanthohumol |
| WO2009067541A2 (en) * | 2007-11-20 | 2009-05-28 | Gilead Sciences, Inc. | Integrase inhibitors |
| KR101700267B1 (ko) * | 2008-07-25 | 2017-01-26 | 비이브 헬쓰케어 컴퍼니 | 화합물 |
| US8217034B2 (en) * | 2008-07-25 | 2012-07-10 | Shionogi & Co., Ltd. | Chemical compounds |
| WO2010011815A1 (en) * | 2008-07-25 | 2010-01-28 | Smithkline Beecham Corporation | Chemical compounds |
| CA2744019C (en) | 2008-12-11 | 2017-03-14 | Shionogi & Co., Ltd. | Synthesis of carbamoylpyridone hiv integrase inhibitors and intermediates |
| TWI518084B (zh) | 2009-03-26 | 2016-01-21 | 鹽野義製藥股份有限公司 | 哌喃酮與吡啶酮衍生物之製造方法 |
| PT3494972T (pt) * | 2010-01-27 | 2024-02-12 | Viiv Healthcare Co | Combinações de dolutegravir e lamivudina para o tratamento de infeção pelo hiv |
| TWI582097B (zh) | 2010-03-23 | 2017-05-11 | Ｖｉｉｖ醫療保健公司 | 製備胺甲醯吡啶酮衍生物及中間體之方法 |
| US20120142701A1 (en) * | 2010-05-28 | 2012-06-07 | The University Of Hong Kong | Compounds and methods for the treatment of proliferative diseases |
| US9238643B2 (en) | 2010-09-06 | 2016-01-19 | Guangzhou Institutes Of Biomedicine And Health, Chinese Academy Of Sciences | Amide compounds |
| ES2602794T3 (es) | 2011-03-31 | 2017-02-22 | Pfizer Inc | Piridinonas bicíclicas novedosas |
| KR101365849B1 (ko) * | 2012-03-28 | 2014-02-24 | 경동제약 주식회사 | 솔리페나신 또는 그의 염의 제조방법 및 이에 사용되는 신규 중간체 |
| UA110688C2 (uk) | 2012-09-21 | 2016-01-25 | Пфайзер Інк. | Біциклічні піридинони |
| CN118286245A (zh) | 2014-12-26 | 2024-07-05 | 埃莫里大学 | N4-羟基胞苷和衍生物及与其相关的抗病毒用途 |
| WO2016125048A1 (en) | 2015-02-03 | 2016-08-11 | Pfizer Inc. | Novel cyclopropabenzofuranyl pyridopyrazinediones |
| US11331331B2 (en) | 2017-12-07 | 2022-05-17 | Emory University | N4-hydroxycytidine and derivatives and anti-viral uses related thereto |
| WO2019113523A1 (en) * | 2017-12-08 | 2019-06-13 | Ashok Bajji | Compounds and therapeutic uses thereof |
| CN111484529A (zh) * | 2019-01-28 | 2020-08-04 | 奥锐特药业股份有限公司 | 一种合成替诺福韦单苯酯的方法 |
| CN112946154B (zh) * | 2021-02-05 | 2022-10-25 | 石家庄四药有限公司 | 他汀类药物起始物料及其对映异构体的hplc检测方法 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH385846A (de) * | 1960-03-31 | 1964-12-31 | Geigy Ag J R | Verfahren zur Herstellung von neuen 7-Acyl-8-hydroxy-chinolinen und ihre Verwendung als Fungizide und Bakterizide im Pflanzen- und Materialschutz |
| US4816570A (en) * | 1982-11-30 | 1989-03-28 | The Board Of Regents Of The University Of Texas System | Biologically reversible phosphate and phosphonate protective groups |
| US4968788A (en) * | 1986-04-04 | 1990-11-06 | Board Of Regents, The University Of Texas System | Biologically reversible phosphate and phosphonate protective gruops |
| ES2118069T3 (es) * | 1990-09-14 | 1998-09-16 | Acad Of Science Czech Republic | Profarmacos de fosfonatos. |
| US5883255A (en) * | 1990-10-31 | 1999-03-16 | Smithkline Beecham Corporation | Substituted indolizino 1,2-b!quinolinones |
| EP0498722B1 (fr) * | 1991-02-07 | 1997-07-30 | Roussel Uclaf | Dérivés bicycliques azotés, leur procédé de préparation, les intermédiaires obtenus, leur application comme médicaments et les compositions pharmaceutiques les renfermant |
| EP0520573A1 (en) * | 1991-06-27 | 1992-12-30 | Glaxo Inc. | Cyclic imide derivatives |
| US5639881A (en) * | 1991-11-08 | 1997-06-17 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Synthesis and elucidation of pyrimido (4,5-Q) quinazoline derivatives |
| TW304945B (enExample) * | 1992-06-27 | 1997-05-11 | Hoechst Ag | |
| US5798340A (en) * | 1993-09-17 | 1998-08-25 | Gilead Sciences, Inc. | Nucleotide analogs |
| PT736020E (pt) * | 1993-12-17 | 2000-10-31 | Procter & Gamble | Compostos 6-(2-imidazolinilamino)quinolina uteis como alfa-2 adrenoceptor agonistas |
| US5538988A (en) * | 1994-04-26 | 1996-07-23 | Martinez; Gregory R. | Benzocycloalkylazolethione derivatives |
| DE19613591A1 (de) * | 1996-04-04 | 1997-10-09 | Hoechst Ag | Substituierte-Chinolin-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung |
| US5854275A (en) * | 1996-05-16 | 1998-12-29 | Pfizer Inc. | Cyclic imide derivatives |
| AU4172197A (en) * | 1996-09-10 | 1998-04-02 | Pharmacia & Upjohn Company | 8-hydroxy-7-substituted quinolines as anti-viral agents |
| DE19738005A1 (de) * | 1997-08-30 | 1999-03-04 | Bayer Ag | Verwendung von substituierten 1,1-Bisphosphonaten |
| US6312662B1 (en) * | 1998-03-06 | 2001-11-06 | Metabasis Therapeutics, Inc. | Prodrugs phosphorus-containing compounds |
| MXPA00012248A (es) * | 1998-06-10 | 2003-04-25 | Arena Pharm Inc | Incrementadores de acetilcolina. |
| WO2000000475A1 (en) * | 1998-06-30 | 2000-01-06 | Du Pont Pharmaceuticals Company | Substituted quinolin-2(1h)-ones useful as hiv reverse transcriptase inhibitors |
| US6187907B1 (en) * | 1998-08-31 | 2001-02-13 | James Chen | Triple helix coil template having a biologically active ligand |
| AU3118200A (en) * | 1998-12-14 | 2000-07-03 | Merck & Co., Inc. | Hiv integrase inhibitors |
| US6245806B1 (en) * | 1999-08-03 | 2001-06-12 | Merck & Co., Inc. | HIV integrase inhibitors |
| WO2001027309A1 (en) * | 1999-10-13 | 2001-04-19 | Merck & Co., Inc. | Hiv integrase inhibitors |
| PE20011349A1 (es) * | 2000-06-16 | 2002-01-19 | Upjohn Co | 1-aril-4-oxo-1,4-dihidro-3-quinolincarboxamidas como agentes antivirales |
| US6525049B2 (en) * | 2000-07-05 | 2003-02-25 | Pharmacia & Upjohn Company | Pyrroloquinolones as antiviral agents |
| AR036256A1 (es) * | 2001-08-17 | 2004-08-25 | Merck & Co Inc | Sal sodica de un inhibidor de integrasa del vih, procesos para su preparacion, composiciones farmaceuticas que lo contienen y su uso para la manufactura de un medicamento |
| JP4942915B2 (ja) * | 2002-04-26 | 2012-05-30 | ギリアード サイエンシーズ， インコーポレイテッド | Ｈｉｖプロテアーゼ阻害剤化合物のホスホネートアナログの細胞蓄積 |
| AU2003301439A1 (en) * | 2002-10-16 | 2004-05-04 | Gilead Sciences, Inc. | Pre-organized tricyclic integrase inhibitor compounds |
-
2005
- 2005-04-11 CA CA002562713A patent/CA2562713A1/en not_active Abandoned
- 2005-04-11 US US11/578,649 patent/US20080076738A1/en not_active Abandoned
- 2005-04-11 PT PT05804767T patent/PT1742642E/pt unknown
- 2005-04-11 JP JP2007508496A patent/JP2007532665A/ja active Pending
- 2005-04-11 SI SI200530545T patent/SI1742642T1/sl unknown
- 2005-04-11 AT AT05804767T patent/ATE411030T1/de not_active IP Right Cessation
- 2005-04-11 EP EP05804767A patent/EP1742642B1/en not_active Expired - Lifetime
- 2005-04-11 ES ES05804767T patent/ES2315922T3/es not_active Expired - Lifetime
- 2005-04-11 DK DK05804767T patent/DK1742642T3/da active
- 2005-04-11 WO PCT/US2005/012520 patent/WO2005117904A2/en not_active Ceased
- 2005-04-11 PL PL05804767T patent/PL1742642T3/pl unknown
- 2005-04-11 AU AU2005249363A patent/AU2005249363A1/en not_active Abandoned
- 2005-04-11 DE DE602005010413T patent/DE602005010413D1/de not_active Expired - Fee Related
- 2005-04-14 US US11/106,363 patent/US20060116356A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007532665A5 (enExample) | ||
| TWI243176B (en) | Chemical compounds comprising nucleoside phosphoramidates, their preparation and their therapeutic uses, and pharmaceutical compositions comprising the compounds | |
| ES2489645T3 (es) | Compuestos y métodos para inhibir la interacción de proteínas BLC con compañeros de unión | |
| JP3121343B2 (ja) | ポリ―４―アミノ―２―カルボキシ―１―メチル化合物の新規ウレイド誘導体 | |
| JP6031122B2 (ja) | 抗微生物療法のための三環式ホウ素化合物 | |
| AU2020323429A1 (en) | Urea compound for antagonizing LPA1 receptor | |
| JPH0623193B2 (ja) | 新規なジスタマイシンａ同族体、その製造方法およびそれを含有する医薬組成物 | |
| JP2006501202A5 (enExample) | ||
| JP4312264B2 (ja) | アクリロイル置換ジスタマイシン誘導体、その製造法、および抗腫瘍および抗ウイルス剤としてのその使用 | |
| JP2004506606A (ja) | 抗ウイルスピリミジンヌクレオシド類 | |
| KR20010103782A (ko) | 항염증성, 진통성 및 항혈전 활성을 갖는 니트록시 유도체 | |
| HU213507B (en) | Process for producing substituted acryloyl-pyrrole derivatives and pharmaceutical compositions comprising same | |
| CA2271299A1 (en) | Benzoheterocyclic distamycin derivatives, process for preparing them, and their use as antitumor and antiviral agents | |
| FR2585019A1 (fr) | Derives de distamycine et leur procede de fabrication | |
| JPH08508720A (ja) | ピロールーアミジン化合物およびその薬剤的に受容できる塩、その製造法ならびにこれを含む医薬組成物 | |
| DE69705622T2 (de) | Distamycin derivate, verfahren zu ihrer herstellung sowie ihre verwendung als antitumor und antiviral wirkstoffe | |
| JP2007517900A5 (enExample) | ||
| EP2321323B9 (fr) | Derives dimeriques d'artemisinine et application en therapie anticancereuse | |
| PL150841B1 (en) | Purine compounds. | |
| NO20051901L (no) | Nye antimycobakterielle sammensetninger og pyrrole derivater som antimycobakterielle sammensetninger | |
| DE69908371T2 (de) | Thioethergruppen enthaltende distamycin-derivate, verfahren zu ihrer herstellung und ihre verwendung als antitumormittel | |
| JPH02160769A (ja) | 新規な２′―ハロメチリデン、２′―エテニリデン及び２′―エチニルアデノシン誘導体類 | |
| US20070191373A1 (en) | Heterocyclic compounds for use in the treatment of viral infections | |
| JP2007523180A (ja) | Ｈｉｖ感染治療に有用なヌクレオシドホスホネート誘導体 | |
| AU2011271480B2 (en) | Riminophenazines with 2-(heteroaryl)amino substituents and their anti-microbial activity |